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? ORIGINAL ARTICLE ?
A Pilot Study: The Beneficial Effects of Combined Statin-
exercise Therapy on Cognitive Function in Patients with
Coronary Artery Disease and Mild Cognitive Decline
Kensuke Toyama 1-4, Seigo Sugiyama 1,5, Hideki Oka 6, Mari Hamada 6,
Yuri Iwasaki 7, Eiji Horio 2, Taku Rokutanda 2, Shinichi Nakamura 2,
Joshua M. Spin 3,4, Philip S. Tsao 3,4 and Hisao Ogawa 1
Abstract
Objective Hypercholesterolemia, a risk factor in cognitive impairment, can be treated with statins. However,
cognitive decline associated with “statins” (HMG-CoA reductase inhibitors) is a clinical concern. This pilot
study investigated the effects of combining statins and regular exercise on cognitive function in coronary ar-
tery disease (CAD) patients with prior mild cognitive decline.
Methods We recruited 43 consecutive CAD patients with mild cognitive decline. These patients were
treated with a statin and weekly in-hospital aerobic exercise for 5 months. We measured serum lipids, exer-
cise capacity, and cognitive function using the mini mental state examination (MMSE).
Results Low-density lipoprotein cholesterol levels were significantly decreased, and maximum exercise ca-
pacity (workload) was significantly increased in patients with CAD and mild cognitive decline after treatment
compared with before. Combined statin-exercise therapy significantly increased the median (range) MMSE
score from 24 (22-25) to 25 (23-27) across the cohort (p<0.01). Changes in body mass index (BMI) were
significantly and negatively correlated with changes in the MMSE. After treatment, MMSE scores in the sub-
group of patients that showed a decrease in BMI were significantly improved, but not in the BMI-increased
subgroup. Furthermore, the patients already on a statin at the beginning of the trial displayed a more signifi-
cant improvement in MMSE score than statin-naïve patients, implying that exercise might be the beneficial
aspect of this intervention as regards cognition. In a multivariate logistic regression analysis adjusted for age
>65 years, sex, and presence of diabetes mellitus, a decrease in BMI during statin-exercise therapy was sig-
nificantly correlated with an increase in the MMSE score (odds ratio: 4.57, 95% confidence interval: 1.05-
20.0; p<0.05).
Conclusion Statin-exercise therapy may help improve cognitive dysfunction in patients with CAD and pre-
existing mild cognitive decline.
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Introduction
The number of dementia cases in developed countries is
dramatically increasing, and rising health care costs related
to dementia are a large social problem (1). Cardiovascular
diseases, as well as their risk factors, are strongly associated
with cognitive decline (2). Development of effective thera-
peutic strategies for cognitive dysfunction in coronary artery
disease (CAD) patients is therefore an urgent issue.
Statins are effective in reducing cardiovascular events and
are recommended for secondary prevention in all patients
who have CAD and tolerate statin therapy (3). However, the
US Food and Drug Administration and several reviews have
raised concern regarding potential adverse cognitive effects
associated with statins (4-7). Exercise therapy is recom-
mended as a protective factor for cognition in older adults,
as well as CAD patients (8).
We previously reported that exercise combined with
statins is clinically useful and an effective treatment for
CAD patients (9-11). However, the effects of statin-exercise
therapy on cognitive function in CAD patients have not
been fully clarified.
In the present study, we examined whether or not statin-
exercise therapy is beneficial for managing cognitive decline
in patients with CAD and pre-existing mild cognitive im-
pairment.
Materials and Methods
Study population
We performed a prospective observational study to inves-
tigate the clinical significance of regular exercise and statin
treatment in CAD patients with mild cognitive decline. We
recruited 43 consecutive CAD patients with mild cognitive
decline (mini mental state examination [MMSE] score <25).
All patients were referred to our hospital for low-density
lipoprotein (LDL) cholesterol-lowering therapy with statins
in order to achieve guideline goals and underwent cardiac
rehabilitation therapy at the Division of Cardiology, Hito-
yoshi Medical Center between April 2011 and August 2014.
Patients who could not perform cardiopulmonary exercises
or undergo MMSE tests during the study period were ex-
cluded.
Study design
The patients performed weekly 30-minute in-hospital
aerobic exercises on ergometer-equipped bicycles. The aero-
bic exercises were based on anaerobic thresholds that were
evaluated with cardiopulmonary exercise tests. Patients per-
formed the exercises for 5 months. An experienced regis-
tered exercise rehabilitation instructor instructed all of the
patients regarding the performance of 30-minute walking or
cycle ergometer exercises at home to a Borg scale rating of
12-13. All of the patients were treated with one of a variety
of statins to achieve guideline goal levels for LDL (<70 mg/
dL). Thirty statin-naive subjects were started on a de novo
statin. Ten patients with pre-existing statin treatment re-
mained on their current dose and statin, two patients were
switched to similar-intensity therapy, and one patient had
their dose increased. The protocol of the Hitoyoshi Cardio-
vascular Rehabilitation Study (HARVEST), which is evalu-
ating the efficacy of exercise therapy on patients with
cardiovascular disease and is registered with the UMIN
protocol registration system (identification number UMIN
000015544; https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?
function=brows&action=brows&recptno=R000018044&type
=summary&language=E), was approved by the Institutional
Review Board of the Hitoyoshi Medical Center in Ku-
mamoto, Japan. A signed consent form was obtained from
each patient. The methods in this study were performed in
accordance with approved guidelines.
Home exercise instructions
All of the patients were instructed to perform exercises at
home under the supervision of a registered exercise rehabili-
tation instructor, as previously described (9). The patients
maintained personal healthcare logs in which they recorded
their daily blood pressure, body weight, and exercises that
were performed at home. Patients who did not complete the
home exercises received repeat instruction and were asked
again to perform the training.
Blood biochemistry
Venous blood samples were collected before the exercise
test.
Cognitive assessment
The MMSE test, a brief 30-point questionnaire, was con-
ducted by a single trained technician at baseline and at the
end of treatment. Subjects who scored below 25 were con-
sidered to have mild cognitive impairment.
Cardiopulmonary exercise test
An individually optimized 5-, 10-, 15-, and 20-Watt ramp-
up exercise protocol on an electromagnetically braked cycle
ergometer (Well Bike BE-250; Cat Eye Co., Osaka, Japan)
with blood pressure and heart rate monitoring was per-
formed in a temperature-controlled room (23-25°C), as pre-
viously described (9). Respiratory gas was sampled from a
mouthpiece, and minute ventilation, carbon dioxide in ex-
pired air, oxygen in inspired air, ventilatory equivalent for
carbon dioxide, and ventilatory equivalent for oxygen were
measured for each breath using a breath-by-breath gas ana-
lyzer (AE310S; Minato Medical Science, Osaka, Japan).
Peak oxygen uptake, anaerobic threshold, and maximum
workload were evaluated at baseline and at the end of treat-
ment.
Statistical analyses
We used the Shapiro-Wilk test to determine whether the
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Table?1.?Patients’ Characteristics.
All patients (n = 43)
Age (years) 71 ± 8
Male, n (%) 35 (81)
Angina pectoris, n (%) 9 (21)
Myocardial infarction, n (%) 29 (67)
Heart failure, n (%) 11 (26)
Cerebral stroke, n (%) 3 (7)
Risk factors
Hypertension, n (%) 32 (74)
Diabetes mellitus, n (%) 15 (35)
Dyslipidemia, n (%) 34 (79)
Chronic kidney disease, n (%) 20 (47)
Current smoking, n (%) 5 (12)
Medical therapies
Aspirin, n (%) 42 (98)
Anticoagulant, n (%) 9 (21)
Angiotensin II receptor blocker, n (%) 13 (30)
Angiotensin-converting enzyme inhibitor, n (%) 23 (53)
Diuretic, n (%) 12 (28)
Calcium channel blockers, n (%) 20 (47)
?-blockers, n (%) 24 (56)
Nitrate, n (%) 9 (21)
Oral hypoglycemic agents, n (%) 6 (14)
Insulin, n (%) 4 (9)
Data are mean ± SD or n (%). 
samples were normally distributed. Depending on the distri-
bution of data, the paired Student’s t-test or Wilcoxon test
was used to analyze the effects of 5 months’ treatment.
Pearson or Spearman correlation tests were used to analyze
correlations between changes in the MMSE and changes in
other parameters. To determine the independent association
between changes in the MMSE and changes in body mass
index (BMI), we adjusted for the effects of other covariates
on the cognitive function with multivariate linear regression
analysis with forced inclusion of the variables of age, sex,
and the presence of hypertension, diabetes mellitus, and
cerebral stroke. Univariate and multivariate logistic regres-
sion analyses were used to assess the baseline parameters,
risk factors, and medications that were correlated with an
elevation in MMSE score (ΔMMSE = [MMSE score after 5
months] - [baseline MMSE score]; cutoff value of ΔMMSE =
1.0, median). There were a total of four missing data-points
for HbA1c in non-diabetic patients (two missing baselines,
and two separate patients missing 5-month data). The data
are expressed as the mean±standard deviation, or median
value. A value of p<0.05 was considered statistically signifi-
cant. All statistical analyses were performed using the IBM
SPSS Statistics software program, Version 21.0 (IBM Corp.,
Armonk, NY, USA).
Results
Patients’ characteristics
The patients’ baseline characteristics are shown in Ta-
ble 1. Forty-three CAD patients (aged 71±8 years, 81%
male) were included.
Effect of statin-exercise therapy on the cognitive
function and other parameters
Five months of combined statin-exercise therapy signifi-
cantly improved the cognitive decline on average, as meas-
ured by the MMSE test (Figure A). Table 2 shows the ef-
fects of statin-exercise therapy on various parameters. The
cardiopulmonary function, as measured by the maximum
workload capacity, significantly improved after treatment.
The average total cholesterol and LDL cholesterol levels
were significantly decreased after treatment compared with
before treatment.
Effect of pre-treatment statin and statin types on
cognitive outcome
Thirteen patients were on pre-existing statin therapy at the
beginning of the statin-exercise therapy period. Overall, this
subgroup experienced little-to-no changes in their statin regi-
men at the initiation of the trial. These patients displayed a
significant increase in the MMSE score (p<0.009), which
was not observed in the statin-naïve patients (Figure B). No-
tably, the average BMI was not markedly different between
the pre-existing statin treatment and statin-naïve groups after
treatment (25.8±4.2 to 26.1±3.6 kg/m2, p=0.521; 23.6±3.2 to
23.5±3.2 kg/m2, p=0.611, respectively).
Further, the mean (range) MMSE score of lipophilic
statins users (n=26) increased significantly from 24 (22-25)
to 25 (23-28) (p=0.005). In contrast, hydrophilic statin users
(n=17) saw no marked changes (25 [22-26] to 24 [23-27],
p=0.217).
Baseline diabetes mellitus and improvement of the
cognitive function
Fifteen diabetic CAD patients were included in this study.
Six diabetic patients were taking oral glycemic agents, while
four separate patients were taking insulin (Table 1). While
the anti-diabetic agents might have had effects on BMI and
cognition, a univariate logistic regression analysis showed
that neither oral hypoglycemic agents nor insulin correlated
with an increase in the MMSE score (Table 3) or a decrease
in the BMI (odds ratio: 1.85, p=0.489; and 0.53, p=0.601,
respectively). Further, although the baseline fasting blood
glucose level, HbA1c level, and oral hypoglycemic agents
were not associated with cognitive response (Table 3), a uni-
variate logistic regression analysis showed that the presence
of diabetes mellitus (DM) was significantly negatively corre-
lated with an increase in the MMSE score (odds ratio: 0.24,
p<0.05). The MMSE in non-diabetic CAD patients signifi-
cantly increased after treatment compared with before treat-
ment, with no marked changes in the diabetic patients (Fig-
ure C).
Effects of statin-exercise therapy-associated
changes in BMI on cognitive decline
Although the average BMI did not change markedly
across the study group (Table 2), changes in the BMI were
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Figure.?The effect of statin-exercise therapy on cognition in CAD patients with mild cognitive de-
cline. (A) Box-and-whisker plot showing the effect of combined exercise and statin treatment for 5 
months on the cognitive function using the MMSE test. (B) Box-and-whisker plot showing the effect 
of statin-exercise therapy on the MMSE score between the statin-naïve group and pre-existing statin 
groups. (C) Box-and-whisker plot showing the effect of combined exercise and statin therapy for 5 
months on the MMSE scores between patients without DM (non-DM) and those with DM. (D) A re-
gression analysis showing the correlation between changes in the BMI and changes in the MMSE 
score. (E) Box-and-whisker plot showing the effect of statin-exercise therapy on the MMSE score 
between the BMI-increased and BMI-decreased groups. (A, B, C, and E) In these box-and-whisker 
plots, the lines within the boxes represent the median values, the upper and lower lines of the boxes 
represent the 25th and 75th percentiles, respectively, and the upper and lower bars outside the boxes 
represent the 90th and 10th percentiles, respectively. MMSE: mini mental state examination, BMI: 
body mass index, 5 mo: 5 months, n: number of patients in each group
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inversely correlated with changes in the MMSE (Figure D,
Table 4). After adjusting for age, sex, and the presence of
hypertension, DM, and cerebral stroke, a multivariate linear
regression analysis showed that changes in the BMI were
still significantly associated with changes in the MMSE (Ta-
ble 5). Furthermore, there was a significant inter-subgroup
difference in changes in the BMI between the MMSE-
increased (ΔMMSE >1.0) and the MMSE-decreased groups
(ΔMMSE 1.0) (Table 6).
The MMSE in the BMI-decreased group (ΔBMI = [BMI
after 5 months] - [baseline BMI]; ΔBMI <0.0) was signifi-
cantly elevated after treatment compared with before treat-
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Table?2.?Effects of Statin-exercise Treatment on Various Parameters.
All patients (n=43) Baseline 5 months p value
Systolic blood pressure, mmHg 120 ± 14 122 ± 15 0.298
Diastolic blood pressure, mmHg 69 ± 9 70 ± 10 0.451
Body mass index, kg/m2 24.3 ± 3.6 24.3 ± 3.5 0.966
Abdominal circumference, cm 88 (84 to 94) 87 (81 to 93) 0.070
Anaerobic threshold, mL/min/kg 10.3 ± 2.0 10.7 ± 2.0 0.238
Peak oxygen uptake, mL/min/kg 15.7 ± 3.9 16.4 ± 3.0 0.067
Maximum work load, max Watts 77 (53 to 95) 82 (63 to 97) 0.003
Left ventricular ejection fraction, % 59.1 ± 11.8 61.8 ± 7.8 0.086
Hemoglobin, g/dL 13.7 ± 1.5 13.7 ± 1.5 0.719
Albumin, g/dL 3.9 (3.5 to 4.1) 4.2 (4.0 to 4.6) < 0.001
Estimated glomerular filtration rate, mL/min/1.73 m2 58.9 (53.4 to 66.4) 59.7 (51.3 to 67.9) 0.915
Total cholesterol, mg/dL 185 (153 to 204) 145 (126 to 156) < 0.001
High-density lipoprotein cholesterol, mg/dL 45 (39 to 56) 47 (42 to 57) 0.199
Low-density lipoprotein cholesterol, mg/dL 115 (91 to 127) 69 (57 to 82) < 0.001
Triglycerides, mg/dL 116 (76 to 163) 108 (66 to 152) 0.343
HbA1c, % 5.7 (5.5 to 6.4) 5.8 (5.5 to 6.3) 0.819
Data are mean ± SD, or median (25-75%).
Table?3.?Logistic Regression Analysis for Elevation of Mini Mental State Examination Scores 
among Baseline Parameters.
All patients (n=43) 
Univariate Multivariate
(Hosmer–Lemeshow test; 
p=0.204)
OR (95% CI) p value OR (95% CI) p value
Age, years 1.04 (0.96 to 1.13) 0.311
?65 years old, yes 1.98 (0.48 to 8.13) 0.342 1.54 (0.32 to 7.49) 0.593
Sex, male 1.77 (0.36 to 8.55) 0.480 2.20 (0.32 to 15.0) 0.422
Systolic blood pressure, mmHg 1.01 (0.96 to 1.05) 0.769
Diastolic blood pressure, mmHg 0.99 (0.93 to 1.07) 0.873
Body mass index, kg/m2 0.99 (0.84 to 1.17) 0.897
Decrease in body mass index, yes 3.74 (1.01 to 13.9) 0.049 4.57 (1.05 to 20.0) 0.043
Abdominal circumference, cm 0.98 (0.91 to 1.06) 0.602
Decrease in Abdominal circumference, yes 1.63 (0.48 to 5.47) 0.433
Anaerobic threshold, mL/min/kg 1.01 (0.75 to 1.37) 0.935
Peak oxygen uptake, mL/min/kg 0.98 (0.84 to 1.15) 0.789
Maximum work load, max Watts 1.00 (0.98 to 1.02) 0.896
Left ventricular ejection fraction, % 1.00 (0.95 to 1.06) 0.944
Hemoglobin, g/dL 0.92 (0.65 to 1.32) 0.668
Albumin, g/dL 1.05 (0.19 to 5.63) 0.959
Estimated glomerular filtration rate, mL/min/1.73 m2 1.03 (0.97 to 1.08) 0.359
Total cholesterol, mg/dL 0.99 (0.98 to 1.01) 0.262
High-density lipoprotein cholesterol, mg/dL 1.00 (0.95 to 1.05) 0.913
Low-density lipoprotein cholesterol, mg/dL 0.99 (0.98 to 1.01) 0.459
Triglycerides, mg/dL 1.00 (0.99 to 1.00) 0.246
Fasting blood glucose, mg/dL 0.99 (0.96 to 1.01) 0.280
HbA1c, % 0.79 (0.40 to 1.57) 0.505
Mini Mental State Examination score 0.75 (0.55 to 1.03) 0.076
Risk factors
Hypertension, yes 1.20 (0.30 to 4.74) 0.795
Diabetes mellitus, yes 0.24 (0.06 to 0.93) 0.039 0.25 (0.06 to 1.15) 0.075
Dyslipidemia, yes 0.71 (0.16 to 3.12) 0.651
Chronic kidney disease, yes 0.51 (0.15 to 1.73) 0.282
Cerebral stroke, yes 0.50 (0.04 to 5.97) 0.584
Current smoking, yes 0.23 (0.02 to 2.20) 0.200
Medical therapies
Aspirin, yes 0.00 (0.00 to ) 1.000
Anticoagulant, yes 5.00 (0.90 to 27.7) 0.066
Angiotensin II receptor blocker, yes 0.86 (0.23 to 3.16) 0.817
Angiotensin-converting enzyme inhibitor, yes 0.92 (0.28 to 3.04) 0.887
Diuretic, yes 1.70 (0.44 to 6.55) 0.440
Calcium channel blockers, yes 0.75 (0.23 to 2.50) 0.639
?-blockers, yes 0.52 (0.15 to 1.76) 0.293
Nitrate, yes 1.41 (0.32 to 6.16) 0.651
Oral hypoglycemic agent, yes 1.06 (0.19 to 5.93) 0.951
Insulin, yes 1.05 (0.13 to 8.24) 0.961
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Table?4.?Correlations between Changes in the Mini Mental State Ex-
amination Score and Each Parameter.
All patients (n=43) r p value
Change in systolic blood pressure, mmHg ?0.165 0.290
Change in diastolic blood pressure, mmHg ?0.269 0.082
Change in body mass index, kg/m2 ?0.348 0.022
Change in abdominal circumference, cm ?0.046 0.770
Change in anaerobic threshold, mL/min/kg ?0.144 0.357
Change in peak oxygen uptake, mL/min/kg ?0.088 0.573
Change in maximum work load, max Watts ?0.050 0.748
Change in left ventricular ejection fraction, % 0.053 0.738
Change in hemoglobin, g/dL ?0.198 0.203
Change in albumin, g/dL ?0.233 0.133
Change in estimated glomerular filtration rate, mL/min/1.73 m2 ?0.012 0.939
Change in total cholesterol, mg/dL ?0.010 0.951
Change in high-density lipoprotein cholesterol, mg/dL 0.131 0.404
Change in low-density lipoprotein cholesterol, mg/dL ?0.111 0.479
Change in triglycerides, mg/dL 0.166 0.288
Change in HbA1c, % 0.220 0.179
Table?5.?Multiple Regression Analysis of Changes in the Mini 
Mental State Examination.
Variable Regression
coefficient (?)
95% CI p value
Age, years 0.014 ?0.11 to 0.12 0.926
Sex, male 0.079 ?1.53 to 2.60 0.601
Hypertension, yes 0.247 ?0.36 to 3.35 0.111
Diabetes mellitus, yes ?0.254 ?3.09 to 0.29 0.101
Cerebral stroke, yes 0.100 ?2.14 to 4.21 0.513
Changes in body mass index, kg/m2 ?0.347 ?1.51 to ?0.08 0.030
r2 = 0.274. 
ment, while there was no marked MMSE change in the
BMI-increased group (ΔBMI 0.0) (Figure E). On examin-
ing other patient characteristics (shown in Table 7), while
the abdominal circumference in the BMI-increased group
did not change markedly, that of the BMI-decreased group
decreased significantly (Table 7). However, univariate logis-
tic regression and linear regression analyses showed that the
abdominal circumference was not associated with the
MMSE score improvement (Table 3, 4). Additionally, while
the average baseline renal function and left ventricular ejec-
tion fraction in the BMI-increased patients were significantly
lower than in the BMI-decreased patients, a univariate logis-
tic regression analysis showed no association between these
variables and the MMSE score (Table 3). Finally, an analy-
sis showed that both a decrease in the BMI, and the absence
of baseline DM were significantly correlated with an eleva-
tion in the MMSE score in response to statin-exercise ther-
apy (BMI, odds ratio: 3.74, p<0.05; DM, 0.24, p<0.05, Ta-
ble 3). In multivariate logistic regression analysis adjusted
for age >65 years of age, sex, and the presence of DM, a
decrease in the BMI with statin-exercise therapy remained
significantly correlated with an elevation in the MMSE score
(odds ratio: 4.57, p<0.05, Table 3).
Discussion
The major finding of the present pilot study is that a
combination of statins and regular exercise therapy appeared
to significantly ameliorate cognitive dysfunction in patients
already displaying mild cognitive dysfunction. This benefi-
cial effect correlated with treatment-associated decrease in
the BMI in CAD patients with mild cognitive decline as
well as in those with pre-existing statin therapy.
Statins are an established therapy for reducing the risk of
cardiovascular events. We previously reported the beneficial
effects of statin-exercise treatment on CAD (9-11). Recently,
perhaps because dietary control in statin users has been less
emphasized as a therapeutic approach, high calorie and fat
intake has been observed in many statin users, accompanied
by higher BMI (vs. non-statin users) (12). High-calorie diets
(and to a lesser extent fat intake) have a well-established
role in the development of obesity and diabetes, which in-
turn are risk factors associated with the pathogenesis of cog-
nitive decline (13). The potential adverse effects of statins
on the cognitive function are a concerning issue. Notably,
some of the beneficial effects of exercise on the MMSE in
our cohort were absent in the cohort that started taking a
statin de novo.
Exercise is known to exert beneficial effects on cogni-
tion (14, 15); indeed, a very recent meta-analysis showed
that aerobic exercise had a significant protective effect on
cognitive dysfunction in older adults with mild cognitive im-
pairment (16). However, weight loss per se is often seen in
the course of dementia, particularly in Alzheimer’s dis-
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Table?6.?Effects of Statin-exercise Treatment on Various Parameters in the Mini Mental State Ex-
amination Score-decreased and -increased Groups.
Mini Mental State Examination
Score -decreased Group (n = 22)
Mini Mental State Examination
Score -increased Group (n = 21)
Baseline 5 months Baseline 5 months
Systolic blood pressure, mmHg 119 ± 15 123 ± 15 120 ± 13 122 ± 15
Change in systolic blood pressure + 4 ± 19 + 2 ± 16
Diastolic blood pressure, mmHg 69 ± 10 73 ± 10 69 ± 8 68 ± 9
Change in diastolic blood pressure + 3 ± 13 - 1 ± 11
Body mass index, kg/m2 24.3 ± 3.4 24.7 ± 3.3 24.2 ± 3.9 23.8 ± 3.7
Change in body mass index + 0.4 ± 1.1 - 0.4 ± 1.1 ‡
Abdominal circumference, cm 88.8 (83.5 to 94.9) 86.3 (81.8 to 92.9) 88.0 (84.0 to 89.5) 87.0 (80.3 to 92.5)
Change in abdominal circumference - 1.5 ± 5.6 - 1.4 ± 4.1 
Anaerobic threshold, mL/min/kg 10.3 ± 1.9 10.7 ± 2.0 10.4 ± 2.2 10.7 ± 2.0
Change in anaerobic threshold + 0.4 ± 1.8 + 0.4 ± 2.4
Peak oxygen uptake, mL/min/kg 15.9 ± 3.6 16.4 ± 3.0 15.5 ± 4.2 16.3 ± 3.1
Change in peak oxygen uptake + 0.6 ± 2.3 + 0.8 ± 2.6
Maximum work load, max Watts 77.0 ± 23.9 81.0 ± 23.8 * 75.9 ± 29.6 79.1 ± 23.1
Change in maximum work load + 4 ± 7 + 3 ± 17
Left ventricular ejection fraction, % 59.0 ± 11.8 61.8 ± 8.2 59.2 ± 12.0 61.9 ± 7.6
Change in left ventricular ejection fraction + 2.8 ± 10.8 + 2.7 ± 9.7
Hemoglobin, g/dL 13.8 ± 2.0 13.9 ± 1.8 13.5 ± 1.3 13.6 ± 1.2
Change in hemoglobin + 0.1 ± 1.3 + 0.0 ± 1.5
Albumin, g/dL 3.9 (3.6 to 4.1) 4.3 (4.0 to 4.6) † 3.8 (3.5 to 4.2) 4.2 (4.0 to 4.5) †
Change in albumin + 0.4 ± 0.5 + 0.3 ± 0.4
Estimated glomerular filtration rate, 
mL/min/1.73 m2
58.8 (46.4 to 64.1) 58.2 (48.3 to 66.7) 59.1 (54.1 to 68.9) 60.6 (50.0 to 71.5)
Change in estimated glomerular filtration 
rate
-0.2 ± 7.0 -0.1 ± 8.9
Total cholesterol, mg/dL 187 (168 to 203) 148 (134 to 156) † 180 (142 to 209) 145 (119 to 157) †
Change in total cholesterol - 48 ± 45 - 43 ± 44
High-density lipoprotein cholesterol, mg/dL 45 (40 to 57) 46 (41 to 54) 46 (38 to 55) 50 (44 to 59)
Change in high-density lipoprotein 
cholesterol
- 0.5 ± 11.5 + 3.0 ± 9.1
Low-density lipoprotein cholesterol, mg/dL 116 (93 to 128) 76 (67 to 84) † 115 (77 to 128) 61 (56 to 79) †
Change in low-density lipoprotein 
cholesterol
- 45 ± 38 - 46 ± 34
Triglycerides, mg/dL 133 (87 to 176) 113 (84 to 152) 92 (62 to 134) 88 (61 to 159)
Change in triglycerides - 24 ± 78 - 3 ± 101
Mini Mental State Examination score 24 (23 to 25) 23 (22 to 25) 23 (22 to 25) 27 (25 to 28) †
Change in Mini Mental State Examination 
score
- 0.8 ± 1.7 + 3.5 ± 1.4 ‡
Data are mean ± SD, or median (25% to 75%). Mini Mental State Examination Score-decreased (????E ?1.0) and 
-increased (????E >1.0) Groups *p < 0.05, †p < 0.01 compared with the respective baseline values; ‡ p < 0.05 compared 
with the Mini Mental State Examination Score-decreased Group.  
ease (17). In fact, low BMI as well as weight-loss were the
predominant risk factors for mild cognitive impairment-to-
dementia conversion in aged subjects with cognitive de-
cline (18). This likely relates to a diminished appetite and
not increased physical activity. To prevent further progres-
sion of dementia in CAD patients with cognitive decline, we
suspect that body weight management through exercise dur-
ing statin therapy may be crucial in order for patients to ex-
perience maximal benefit.
The findings of this study could lead to novel and practi-
cal therapeutic approaches to prevent development and/or
limit progression of cognitive decline in CAD patients.
However, to confirm the importance of combined statin-
exercise therapy, further large prospective clinical studies are
required; for example, comparing the cognitive outcomes
among independent groups receiving exercise or statin, a
statin-exercise combination group, and a non-exercise (con-
trol) group. Standardization of statin dosing and type are
also crucial, as the present pilot study suggests that the ef-
fects of the combination of certain statin therapy types with
exercise in CAD patients should be evaluated. The MMSE
score in lipophilic statins users increased significantly over
the study period, while hydrophilic statin users saw no
marked change. Hydrophilic statins are less permeable
across the blood-brain barrier than lipophilic statins in
model systems (19), raising the question of what impact the
hydrophilicity of a given statin might have on brain disor-
ders and/or healthy brain. Interestingly, Rojas-Fernandez et
al. concluded in a systemic review that hydrophilic statins
(pravastatin and rosuvastatin) might be less likely to contrib-
ute to cognitive impairment, due to their limited penetration
across the blood-brain barrier (20). These elements should
be assessed in combination with exercise in future investiga-
tions of the cognitive function.
Our study has several limitations. First, our study design
prevented effective confirmation of which element of the in-
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Table?7.?Effects of Statin-exercise Treatment on Various Parameters in the Body Mass Index-decreased 
and -increased Groups.
Body Mass Index-decreased 
Group (n =16)
Body Mass Index-increased 
Group (n =27)
Baseline 5 months Baseline 5 months
Systolic blood pressure, mmHg 120 ± 14 123 ± 16 119 ± 14 122 ± 15
Change in systolic blood pressure + 2 ± 14 + 3 ± 20
Diastolic blood pressure, mmHg 68 ± 8 68 ± 8 70 ± 9 72 ± 10
Change in diastolic blood pressure - 1 ± 10 + 3 ± 13
Body mass index, kg/m2 25.0 ± 4.4 23.8 ± 4.1 † 23.8 ± 3.1 24.5 ± 3.1 †
Change in body mass index - 1.2 ± 0.9 + 0.7 ± 0.6 ‡
Abdominal circumference, cm 89.0 (84.1 to 94.6) 85.3 (79.4 to 92.4)* 87.0 (83.5 to 94.0) 87.0 (84.0 to 94.0)
Change in abdominal circumference - 3.5 ± 5.4 - 0.4 ± 3.9
Anaerobic threshold, mL/min/kg 10.9 ± 2.0 11.0 ± 2.0 10.0 ± 2.0 10.5 ± 1.9
Change in anaerobic threshold + 0.2 ± 2.7 + 0.5 ± 1.6
Peak oxygen uptake, mL/min/kg 16.4 ± 3.8 17.0 ± 2.3 15.3 ± 3.9 16.0 ± 3.4
Change in peak oxygen uptake + 0.6 ± 2.9 + 0.8 ± 2.1
Maximum work load, max Watts 79.4 ± 27.2 79.3 ± 18.2 74.7 ± 26.5 80.5 ± 26.0 †
Change in maximum work load 0 ± 17 + 6 ± 9
Left ventricular ejection fraction, % 63.7 ± 11.2 63.2 ± 6.7 56.4 ± 11.4 ‡ 61.0 ± 8.4 *
Change in left ventricular ejection fraction - 0.5 ± 9.7 + 4.6 ± 10.1
Hemoglobin, g/dL 13.7 ± 1.6 13.6 ± 1.3 13.6 ± 1.8 13.8 ± 1.6
Change in hemoglobin - 0.8 ± 1.2 + 0.2 ± 1.4
Albumin, g/dL 3.8 (3.6 to 4.1) 4.2 (4.0 to 4.5) * 3.9 (3.5 to 4.1) 4.3 (4.0 to 4.6) †
Change in albumin + 0.3 ± 0.4 + 0.4 ± 0.5
Estimated glomerular filtration rate, 
mL/min/1.73 m2
59.8 (58.9 to 70.6) 65.1 (55.1 to 73.8) 56.8 (45.8 to 66.0)‡ 55.1 (40.0 to 65.8)
Change in estimated glomerular filtration 
rate
+ 2.0 ± 8.1 - 1.5 ± 7.6
Total cholesterol, mg/dL 188 (166 to 234) 143 (116 to 155) † 180 (152 to 199) 151 (131 to 157) †
Change in total cholesterol - 61 ± 50 - 37 ± 39
High-density lipoprotein cholesterol, mg/dL 49 (38 to 60) 48 (43 to 60) 44 (39 to 53) 47 (41 to 53)
Change in high-density lipoprotein
cholesterol
+ 0.3 ± 11.2 + 1.7 ± 10.1
Low-density lipoprotein cholesterol, mg/dL 116 (96 to 140) 64 (56 to 81) † 114 (87 to 127) 73 (61 to 82) †
Change in low-density lipoprotein 
cholesterol
- 56 ± 46 - 39 ± 26
Triglycerides, mg/dL 98 (67 to 142) 68 (52 to 124) 126 (81 to 169) 121 (88 to 172)
Change in triglycerides - 35 ± 79 - 2 ± 94
Mini Mental State Examination score 24 (22 to 25) 26 (23 to 28) † 24 (22 to 25) 25 (22 to 27)
Change in Mini Mental State Examination 
score
+ 2.3 ± 2.6 + 0.7 ± 2.6
Data are mean ± SD, or median (25% to 75%). Body Mass Index-decreased (?BMI <0.0) and -increased (?BMI ?0.0) Groups 
*p < 0.05, †p < 0.01 compared with the respective baseline values; ‡ p < 0.05 compared with the Body Mass Index -decreased 
Group. 
tervention improved cognitive function in these CAD pa-
tients, although subgroup analyses suggested that exercise
might be more crucial. Second, the study included only a
small number of patients from a single center.
In conclusion, the combination of statins and exercise ap-
pears to be associated with significant improvement in the
cognition of CAD patients with mild pre-existing cognitive
dysfunction. A decrease in the BMI during therapy was an
independent factor associated with improving cognition.
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